Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma

被引:2
|
作者
Wagner, Sebastian A. [1 ,2 ]
Szczesniak, Pawel P. [1 ]
Voigt, Andrea [3 ]
Graf, Justus F. [3 ]
Beli, Petra [3 ,4 ]
机构
[1] Goethe Univ, Dept Med Hematol Oncol, Sch Med, Frankfurt, Germany
[2] German Canc Consortium DKTK, Heidelberg, Germany
[3] Inst Mol Biol IMB, Mainz, Germany
[4] Johannes Gutenberg Univ Mainz, Inst Dev Biol & Neurobiol IDN, Mainz, Germany
关键词
ALK; fusion kinase; lung cancer; phosphoproteomics; RET; ROS1; GENOMIC CHARACTERIZATION; NETWORKS; ROS1;
D O I
10.1002/pmic.202000283
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Kinase fusions are considered oncogenic drivers in numerous types of cancer. In lung adenocarcinoma 5-10% of patients harbor kinase fusions. The most frequently detected kinase fusion involves the Anaplastic Lymphoma Kinase (ALK) and Echinoderm Microtubule-associated protein-Like 4 (EML4). In addition, oncogenic kinase fusions involving the tyrosine kinases RET and ROS1 are found in smaller subsets of patients. In this study, we employed quantitative mass spectrometry-based phosphoproteomics to define the cellular tyrosine phosphorylation patterns induced by different oncogenic kinase fusions identified in patients with lung adenocarcinoma. We show that exogenous expression of the kinase fusions in HEK 293T cells leads to widespread tyrosine phosphorylation. Direct comparison of different kinase fusions demonstrates that the kinase part and not the fusion partner primarily defines the phosphorylation pattern. The tyrosine phosphorylation patterns differed between ALK, ROS1, and RET fusions, suggesting that oncogenic signaling induced by these kinases involves the modulation of different cellular processes.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
    Ho, H.
    Yeh, Y.
    Hsieh, W.
    Chou, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1926 - S1926
  • [22] CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs)
    Ravanelli, Marco
    Agazzi, Giorgio M.
    Ganeshan, Balaji
    Roca, Elisa
    Tononcelli, Elena
    Bettoni, Valeria
    Caprioli, Alberto
    Borghesi, Andrea
    Berruti, Alfredo
    Maroldi, Roberto
    Farina, Davide
    EUROPEAN JOURNAL OF RADIOLOGY, 2018, 109 : 130 - 135
  • [23] Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro
    Tatematsu, Tsutomu
    Sasaki, Hidefumi
    Shimizu, Shigeki
    Okuda, Katsuhero
    Shitara, Masayuki
    Hikosaka, Yu
    Moriyama, Satoru
    Yano, Motoki
    Brown, Jeffrey
    Fujii, Yoshitaka
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 725 - 730
  • [24] Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways
    Qiao, LY
    Vizzard, MA
    JOURNAL OF COMPARATIVE NEUROLOGY, 2002, 454 (02) : 200 - 211
  • [25] Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
    Kang, Minsu
    Park, Changhee
    Kim, Se Hyun
    Yoon, Sock Won
    Suh, Koung Jin
    Kim, Yu Jung
    Ock, Chan-Young
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    Lee, Jong Seok
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 699 - +
  • [26] Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma
    Okano, Tetsuya
    Kondo, Tadashi
    Fujii, Kiyonaga
    Nishimura, Toshihide
    Takano, Toshimi
    Ohe, Yuichiro
    Tsuta, Koji
    Matsuno, Yoshihiro
    Gemma, Akihiko
    Kato, Harbumi
    Kudoh, Shoji
    Hirohashi, Setsuo
    CLINICAL CANCER RESEARCH, 2007, 13 (03) : 799 - 805
  • [27] Small-cell Lung Cancer Specific Oncogenic Signature Identified By Gene Co-expression Network Analysis
    Udyavar, A.
    Clark, J.
    Zou, Y.
    Callison, C.
    Chen, X.
    Liebler, D.
    Shyr, Y.
    Estrada, L.
    Quaranta, V.
    Massion, P.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S281 - S282
  • [28] Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
    Greulich, Heidi
    Kaplan, Bethany
    Mertins, Philipp
    Chen, Tzu-Hsiu
    Tanaka, Kumiko E.
    Yun, Cai-Hong
    Zhang, Xiaohong
    Lee, Se-Hoon
    Cho, Jeonghee
    Ambrogio, Lauren
    Liao, Rachel
    Imielinski, Marcin
    Banerji, Shantanu
    Berger, Alice H.
    Lawrence, Michael S.
    Zhang, Jinghui
    Pho, Nam H.
    Walker, Sarah R.
    Winckler, Wendy
    Getz, Gad
    Frank, David
    Hahn, William C.
    Eck, Michael J.
    Mani, D. R.
    Jaffe, Jacob D.
    Carr, Steven A.
    Wong, Kwok-Kin
    Meyerson, Matthew
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (36) : 14476 - 14481
  • [29] Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
    Boudny, V
    Nakano, S
    BRITISH JOURNAL OF CANCER, 2002, 86 (03) : 463 - 469
  • [30] Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
    V Boudny
    S Nakano
    British Journal of Cancer, 2002, 86 : 463 - 469